Divis Labs slumps over 9 percent on USFDA observations
New Delhi: Shares of Divis Laboratories Ltd fell as much as 9.4 percent to Rs. 870.1 on USFDA observations.
Observations issued by the USFDA on its Visakhapatnam plant question data integrity and cite inadequate cleaning procedure, according to a BlooombergQuint report.
Divi's Labs had said last week it received six observations from the FDA, saying it was procedural in nature. The drug maker did not immediately respond to Reuters' request for comment on the BlooombergQuint report.
The stock posted its biggest intraday percentage fall since March 21. It had fallen about 28 percent in the last 12 months up to Tuesday's close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd